JW Biotech Signs Exclusive Brand Agreement for Discovery Life Sciences Products in the US

GW Biotech (CEO Yang Jaewon) announced on the 23rd that it has signed an exclusive brand agreement with Discovery Life Sciences (hereinafter referred to as ‘Discovery’), a company specializing in bio samples and biomarkers, to supply Gentest ADME/Tox products to the domestic market.

Discovery’s Gentest ADME/Tox products are a product line used for experiments on drug absorption, distribution, metabolism, excretion, and toxicity, playing an essential role in new drug development and safety evaluation. They provide hepatocytes, microsomes, cytosol, and S9 fractions derived from animals and humans for in vitro experiments. The company explained that thanks to the excellent quality and accuracy of these products, researchers can secure more reliable test results.

Through this agreement, GW Biotech plans to offer more advanced and innovative solutions related to non-clinical trials in the domestic new drug research and development sector. Additionally, it expects performance improvements beyond expectations in the fields of drug metabolism and toxicity research.

Discovery is a global market leader in biospecimen analysis and distribution for the pharmaceutical, biotechnology, and diagnostics industries. It conducts a wide range of integrated biomarker testing services, including genomics, proteomics, molecular pathology, and cell biology.

A GW Biotech official stated, “This contract signing is an important milestone for Discovery’s entry into the domestic market,” adding, “Our company is a bio life science enterprise with over 30 years of accumulated experience and know-how in Korea, and through this agreement, we expect to effectively provide Gentest ADME/Tox products along with broader and more strategic products and services to domestic customers.”

Meanwhile, Discovery recently acquired IVAL (In Vitro ADMET Laboratories), which holds the world’s largest inventory of hepatocytes and related advanced technologies, including Corning’s Gentest division. It is also expanding strategic investments in innovative preclinical development services by acquiring ReachBio Research Labs, which specializes in cell-based analysis.

This content was produced with the assistance of AI translation services.